Improving Bayesian estimation of Vaccine Efficacy

TL;DR

This paper introduces an improved Bayesian method for estimating vaccine efficacy, offering a more robust alternative to traditional exact methods, demonstrated through analysis of the Pfizer COVID-19 vaccine trial data.

Contribution

It presents a full Bayesian approach to vaccine efficacy estimation, enhancing accuracy over existing conditional methods.

Findings

Bayesian method provides more reliable efficacy estimates.

Application to Pfizer data validates the approach.

Potential for improved vaccine trial analysis.

Abstract

A full Bayesian approach to the estimation of Vaccine Efficacy is presented, which is an improvement over the currently used exact method conditional on the total number of cases. As an example, we reconsider the statistical sections of the BioNTech/Pfizer protocol, which in 2020 has led to the first approved anti-Covid-19 vaccine.